Therefore, in our present study, we selected nine potentially functional polymorphisms in IGF1 (rs6214, rs6218, rs35767, rs5742612, and rs5742714) and IGFBP3 (rs2132572, rs2854744, rs2854746 and rs282734), and evaluated their association with risk and prognosis of RCC in a two-stage case-control study. This evidence concerns the gene IGF1 and renal cell adenocarcinoma.